These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 7077464

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
    Niedelman SM.
    Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
    [No Abstract] [Full Text] [Related]

  • 25. Counterfeiting and piracy of pharmaceuticals.
    Grackin A.
    IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698
    [No Abstract] [Full Text] [Related]

  • 26. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries.
    Schwemer WL, Lynch MA.
    J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Recent developments in aluminium contamination of products used in parenteral nutrition.
    Gura KM, Puder M.
    Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):239-46. PubMed ID: 16607123
    [Abstract] [Full Text] [Related]

  • 29. Manufacturing misdeeds cost Abbott record-breaking payment.
    Lewis C.
    FDA Consum; 2000 May; 34(3):38-9. PubMed ID: 11521253
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA.
    Food Drug Law J; 1997 May; 52(1):67-82. PubMed ID: 10346711
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Regulation of plasma derivatives in the U.S.A.
    Finlayson JS.
    Dev Biol Stand; 1993 May; 81():277-81. PubMed ID: 8174815
    [No Abstract] [Full Text] [Related]

  • 34. Validation--how much is required?
    Sharp J.
    PDA J Pharm Sci Technol; 1995 May; 49(3):111-8. PubMed ID: 7613988
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Botanical drugs: a future for herbal medicines.
    Li W.
    J Contemp Health Law Policy; 2002 May; 19(1):117-49. PubMed ID: 12733224
    [No Abstract] [Full Text] [Related]

  • 37. Standardization of forensic drug analyses.
    Frank RS, Gunn JW.
    J Forensic Sci; 1974 Jan; 19(1):163-7. PubMed ID: 4854386
    [No Abstract] [Full Text] [Related]

  • 38. Good validation practices: FDA issues.
    Levchuk JW.
    PDA J Pharm Sci Technol; 1994 Jan; 48(5):221-3. PubMed ID: 8000894
    [No Abstract] [Full Text] [Related]

  • 39. Drug development history, "overview," and what are GCPs?
    Heilman RD.
    Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
    [Abstract] [Full Text] [Related]

  • 40. The drug industry and drug effectiveness.
    Curran WJ.
    N Engl J Med; 1970 Aug 06; 283(6):304-5. PubMed ID: 5427059
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.